7925 patients from the POISE trial were included in this post-hoc analysis regarding neuraxial block. The purpose of this analysis was to determine whether neuraxial block was significantly associated with the primary composite outcome (i.e., cardiovascular death, non-fatal myocardial infarction, or non-fatal cardiac arrest), myocardial infarction, stroke, and clinically-significant hypotension over 30 days post-operation. Results indicated that neuraxial block was associated with an increased risk for the primary composite outcome and myocardial infarction, but not stroke or death. There was a non-significant trend towards neuraxial block being associated with clinically-significant hypotension, and the administration of beta-blockers did not influence these results.